<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02701153</url>
  </required_header>
  <id_info>
    <org_study_id>15-001657</org_study_id>
    <secondary_id>NCI-2016-00202</secondary_id>
    <secondary_id>15-001657</secondary_id>
    <nct_id>NCT02701153</nct_id>
  </id_info>
  <brief_title>Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort</brief_title>
  <official_title>Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Radiological Society of North America</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sarcoma Alliance for Research through Collaboration</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sarcoma Foundation of America</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tower Cancer Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects of hypofractionated radiation therapy in&#xD;
      treating patients with soft tissue sarcomas prior to surgery. Hypofractionated radiation&#xD;
      therapy delivers higher doses of radiation therapy over a shorter period of time and may kill&#xD;
      more tumor cells and have fewer side effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJCETIVES:&#xD;
&#xD;
      I. Grade &gt;= 2 radiation morbidity (subcutaneous tissue fibrosis, joint stiffness, or edema)&#xD;
      at 2 years.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Evaluate local control, regional control, distant metastasis, progression free survival,&#xD;
      and overall survival.&#xD;
&#xD;
      II. Evaluate the functional outcomes as assessed using the musculoskeletal tumor rating scale&#xD;
      (MSTS) and the Toronto Extremity Salvage Score (TESS).&#xD;
&#xD;
      III. Collect germ-line deoxyribonucleic acid (DNA) and nucleic acids from cancer patients to&#xD;
      further investigate the association and identify new germ-line mutations that impact cancer&#xD;
      predisposition.&#xD;
&#xD;
      IV. Investigate the role of germ-line mutations in predicting cancer outcome and response to&#xD;
      therapy.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo hypofractionated radiation therapy on Monday-Friday for 5 days. Beginning&#xD;
      2-12 weeks after completion of radiation therapy, patients undergo surgery.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 3 months and then every 6&#xD;
      months for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2016</start_date>
  <completion_date type="Anticipated">February 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 3, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grade &gt;= 2 radiation morbidity (subcutaneous tissue fibrosis, joint stiffness, or edema)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Interim reports will be prepared every six months until the results of the study are published. In general, the interim reports will contain information about patient accrual rate with projected completion dates, status of question-answer (QA) review and compliance rate of treatment per protocol, and the frequencies and severity of toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Cumulative incidence approach (K-M plots and Cox proportional hazard modeling) will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local failure</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Cumulative incidence approach (Kaplan-Meier [K-M] plots and Cox proportional hazard modeling) will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Cumulative incidence approach (K-M plots and Cox proportional hazard modeling) will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Cumulative incidence approach (K-M plots and Cox proportional hazard modeling) will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional failure</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Cumulative incidence approach (K-M plots and Cox proportional hazard modeling) will be used.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Recurrent Adult Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment (hypofractionated radiation therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo hypofractionated radiation therapy on Monday-Friday for 5 days. Beginning 2-12 weeks after completion of radiation therapy, patients undergo surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional Surgery</intervention_name>
    <description>Undergo surgery</description>
    <arm_group_label>Treatment (hypofractionated radiation therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated Radiation Therapy</intervention_name>
    <description>Undergo hypofractionated radiation therapy</description>
    <arm_group_label>Treatment (hypofractionated radiation therapy)</arm_group_label>
    <other_name>Hypofractionated Radiotherapy</other_name>
    <other_name>hypofractionation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (hypofractionated radiation therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (hypofractionated radiation therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed soft tissue sarcoma of the extremity/trunk&#xD;
&#xD;
          -  Intermediate or high grade sarcoma&#xD;
&#xD;
          -  Resectable primary lesion (patients with pre-existing metastasis will be included if&#xD;
             their primary is still going to be resected)&#xD;
&#xD;
          -  Recurrent, any grade, no previous radiation therapy&#xD;
&#xD;
          -  Karnofsky performance status (KPS) &gt;= 70 or Eastern Cooperative Oncology Group (ECOG)&#xD;
             0 - 2&#xD;
&#xD;
          -  If a woman is of childbearing potential, a negative serum pregnancy test must be&#xD;
             documented&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active treatment of a separate malignancy&#xD;
&#xD;
          -  History of prior irradiation to the area to be treated&#xD;
&#xD;
          -  Pre-operative chemotherapy (post-op acceptable)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Kamrava</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Basehart</last_name>
      <phone>310-267-8954</phone>
      <email>vbasehart@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Anusa Kalbasi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 2, 2016</study_first_submitted>
  <study_first_submitted_qc>March 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2016</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

